At present 67Ga can be considered one of the most widely used viability radiotracers. There is general consensus in the literature that 67Ga has the highest clinical value in the management of lymphoma patients.
Methods
We critically discuss the role of gallium scintigraphy in lymphoma patients on the basis of the experience of the Nuclear Medicine Division at the National Cancer Institute of Milan.
Results and Conclusions
The sensitivity of gallium scan is very high (80-90%) in the staging and follow-up of Hodgkin's disease, and the method is also of great importance in the follow-up of lymphoma patients. We recommend scintigraphy to study the residual mediastinal mass after treatment. Our experiences during the follow-up of 189 lymphoma patients clearly showed the superior performance of gallium scan compared to MRI in the study of the mediastinal region after treatment. Sensitivity and specificity were both very high (90% and 96.9% vs 88.7% and 89.2%, respectively). Gallium scintigraphy can also be used to study the disease-free interval, posttreatment survival, early signs of recurrence and treatment response times. Comparison of the survival curves of 33 patients with diffuse large cell Non-Hodgkin's lymphoma examined at the National Cancer Institute showed a statistically significant difference (logrank test, P=0.0125) between patients with positive and those with negative gallium scan after 4-6 cycles of chemotherapy.
Amsterdam vanJ.A.G., Kluin-NelemansJ.C., Eck-Smit vanB.L.F., PauwelsE.K.J.: Role of Ga-67 scintigraphy in localization of lymphoma.Ann. Hematol, 72: 202–207, 1996.
2.
AndersonK.C., LeonardR.C.F., CanellosG.P., SkarinA.T., KaplanW.D.: High dose gallium imaging in lymphoma.Am. J. Med, 75: 327–331, 1983.
3.
AnghileriL.J., Crone-EscanyeM.C., ThouvenotP.: Mechanism of gallium-67 accumulation by tumors: role of cell membrane permeability.J. Nucl. Med,29: 663, 1988.
4.
ArmitageJ.O., WeisenburgerD.D., HutchinsM.: Chemotherapy for diffuse large cell lymphoma: rapidly responding patients have more durable remissions.J. Clin. Oncol., 4: 160–166, 1986.
5.
BonadonnaG., BrusamolinoE.: Linfomi maligni.In: Manuale di Oncologia Medica.BonadonnaG., Robustelli della CunaG. (Eds.), p. 1011, Masson, Milano, 1991.
6.
BrascoD.J., DurantJ.R., GreenL.E.: The accuracy of retroperitoneal ultrasonography in Hodgkin's disease and non-Hodgkin lymphoma.Radiology,125: 485, 1977.
7.
BrascoD.J.: Tumor localization and treatment planning with ultrasound.Cancer,39: 85, 1977.
8.
CanellosG.P.: Residual mass in lymphoma may not be residual disease (editorial).J. Clin. Oncol.,6: 931, 1988.
9.
CastellaniM.R., GaspariniM., BalleriniE.: Gallium scan in Hodgkin's lymphoma of childhood and youth: a seven years study.First European Symposium on Pediatric Nuclear Medicine, p. 62TorneF.M., HahmK., RocaK. (Eds.), Barcelona, 1992.
10.
ChitambarC.R., SaxD.: Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells.Blood, 80: 505–511, 1992.
11.
ChitambarR.G., ZivkovicZ.: Uptake of Ga-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms.Cancer Res., 47: 3929–3934, 1987.
12.
DeMeesterT.R., GolombH.M., KirhnerP.: The role of gallium-67 scanning in the clinical staging and preoperative evaluation of patients with carcinoma of the lung.Ann. Thorac. Surg., 18: 451–464, 1979.
13.
DevizziL., MaffioliL., BonfanteV., VivianiS., BalzariniL., GaspariniM., ValagussaP., BombardieriE.: Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin's disease.Ann. Oncol.,8(suppl I): 53, 1997.
14.
DonahueD.M., LeonardJ.C., BasmadjianG.P.: Thymic gallium-67 localization in pediatric patients on chemotherapy: concise communication.J. Nucl. Med., 22: 1043–1048, 1981.
15.
DudleyH.C., ImirieG.W.Jr., IstockJ.T.: Deposition of radiogallium in proliferating tissues.Radiology,55: 571, 1950.
16.
EdelingC.J.: Ga-67 imaging in pediatric oncology.Clin. Nucl Med.,8: 205, 1983.
EmeryT., HofferP.B.: Siderophore-mediated mechanism of gallium uptake demonstrated in the microorganism.Ustilago sphaerogena. J. Nucl. Med., 21: 935–939, 1980.
19.
FrontD., Bar-ShalomR., EpelbaumE.: Early detection of lymphoma recurrence with gallium-67 scintigraphy.J. Nucl. Med., 34: 2101–2107, 1993.
20.
FrontD., IsraelO., EpelbaumR.: Ga-67 SPET before and after treatment of lymphoma.Radiology,175: 515, 1990.
21.
FrontD., IsraelO.: The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients.Sem. Nucl. Med., 25: 60–71, 1995.
22.
GamsR.A., WebbJ., GlicksonJ.D.: Serum inhibition of in vitro Ga-67 binding by L-1210 leukemic cells.Cancer Res., 35: 1422–1426, 1976.
23.
GaspariniM., BalzarmiL., CastellaniM.R.: Current role of gallium scan and magnetic resonance imaging in the follow-up of mediastinal Hodgkin's lymphoma.Cancer, 72: 577–584, 1993.
24.
GaspariniM., Tesoro TessJ., MaffioliL.: Clinical utility of gallium scan and magnetic resonance imaging in the follow-up of mediastinal Hodgkin and non-Hodgkin lymphoma.Eur. J. Nucl. Med., 21, suppl. 94A: 1994.
25.
GaspariniM.: Indicatori a tropismo tumorale.In: Progressi della Medicina Nucleare in Oncologia. BuraggiG.L., BombardieriE. (Eds.), p. 134, Class International, Brescia, 1994.
26.
HammersleyP.A.G., ZivanovicM.A.: Gallium-67 uptake in the regenerating rat liver.J. Nucl. Med.,17: 226, 1976.
27.
HarrisA.W., SephtonR.G.: Transferrin promotion of Ga-67 and Fe-59 uptake by cultured mouse myeloma cells.Cancer Res., 3635–3638, 1977.
HofferP.B.: Mechanism of localization.In: Gallium 67 Imaging.HofferP.B., BeckermanC., HenkinR.E., (Eds.), p. 4, John Wiley, New York, 1978.
32.
HoffmanJ.M., WaskinH.A., SchifterT.: FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.J. Nucl. Med., 34: 567–575, 1993.
33.
Howman-GilesR., StevensM., BerginM.: Role of gallium-67 in management of pediatric solid tumours.Aust. Ped. J., 18: 120–125, 1982.
34.
HubnerK.F., AndrewsG.A., HayesR.L.: The use of rare-earth radionuclides and other bone seekers in the evaluation of bone lesions in patients with multiple myeloma or solitary plasmacytoma.Radiology, 125: 171–176, 1977.
35.
HunninghakeG.N., LineB.R., SrapielS.V.: Activation of inflammatory cells increases the localization of gallium-67 at site of disease.Clin. Res., 29: 171–176, 1981.
In SahaG.B.: Fundamentals of Nuclear Pharmacy, Springer Verlag, 3rd edition, New York, Berlin, Heidelberg,1992.
38.
In BaresR.: Assessment of Hematological Malignancies With PET in Clinical PET.BaresR., LucignaniG. (Eds.), pp. 67–73, Kluwer, Boston, 1996.
39.
IosilevskiG., FrontD., BettmanL.: Uptake of gallium-67 citrate and (2-H3) deoxyglucose in the tumor model, following chemotherapy and radiotherapy.J. Nucl. Med., 26: 278–282, 1985.
40.
IsraelO., FrontD., LamL.: Gallium-67 imaging in monitoring lymphoma response to treatment.Cancer,61: 2439, 1988.
KaplanJ., JordanI., SturrockA.: Regulation of the transferrin-independent iron transport system in cultured cells.J. Biol. Chem., 266: 2997–3004, 1991.
43.
KaplanW.D., AndersonK.C., LeonardR.C.F.: High dose gallium imaging in the evaluation of lymphoma.J. Nucl. Med., 24: 50–53, 1983.
44.
KaplanW.D., JochelsonM.S., HermanT.S.: Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large cell lymphoma.J. Clin. Oncol., 8: 1966–1970, 1990.
45.
KaplanW.D., TakvorianT., MorrisJ.H., RumbaughC.L., ConnollyB.T., AtkinsH.L.: Thallium-201 brain tumour imaging: a comparative study with pathologic correlation.J. Nucl. Med., 28: 47–52, 1987.
46.
KennedyS.M., WalkerD.C., BelzbergA.S.: Macrophage accumulation of inhaled gallium-67 citrate in normal lungs.J. Nucl. Med., 26: 1195–1199, 1985.
47.
KingS.C., RemainR.J., ProsnitzL.R.: Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease.J. Clin. Oncol., 12: 306–310, 1994.
48.
KubotaK., IshiwataK., KubotaR.: Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose, or fluorine-18-fluo-rodeoxyuridine, L[methyl-14C]methionine, [6-3H]thymidine, and gallium-67.J. Nucl. Med., 32: 2118–2123, 1991.
49.
LambertR., BissonG., LamourouxG.: Gallium thoracic scan and pleural disease in asbestos workers.J. Nucl. Med., 26: 600–605, 1982.
50.
LarsonS.M., RaseyJ.S., AllenD.R.: A transferrin-mediated uptake of Ga-67 by EMT-6 sarcoma.1. Studies in tissue cultures. J. Nucl. Med., 20: 837–842, 1979.
51.
LineB.R.: Scintigraphic studies of inflammation in diffuse lung disease.Radiol. Clin. North. Am., 29: 1095–1114, 1991.
52.
LomasF.R., DibosP.E., WagnerH.N.: Increased specificity of liver scanning with the use of gallium-67 citrate.N. Engl. J. Med.,286: 1323, 1972.
53.
MacMahonH.: Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer.Cancer, 64: 1404–1408, 1989.
54.
MatsunoS., TanabeM., KawasakiY.: Effectiveness of planar image and single photon emission tomography of thallium-201 compared with gallium-67 in patients with primary lung cancer.Eur. J. Nucl. Med., 19: 86–95, 1992.
55.
McLaughlinA.F., ChuJ., Howman-GilesR.: Whole body gallium scanning in malignant lymphoma –- its role in 1980.Aus. NZ. J. Med.,11: 436–444, 1981.
56.
McLaughlinA.F., SoutheeA.E.: Gallium scintigraphy in tumor diagnosis and management. In: Nuclear Medicine, MurrayI.P.C., EllP. (Eds.), pp. 711–725, Churchill-Livingstone, Edinburgh, London, 1994.
57.
NeumannR.D., HofferP.B.: Gallium for detection of malignant disease.In: Diagnostic Nuclear Medicine,GottschalkA., HofferP.B., PotchenE. (Eds.), 2nd edn., pp. 1076–1089, Williams and Wilkins, Baltimore, 1988.
58.
NijmanR.S., RehnS.M., GlimeliusB.L.G.: Residual mediastinal masses in Hodgkin's disease: prediction of size with MR imaging.Radiology,170: 435, 1989.
59.
Nuclear Medicine Procedure Manual 1997-1998,KlingensmithW.C., EshimaD., GoddardJ. (Eds.), Wick, Englewood, USA, 1997.
60.
OhkuboY., SasayamaA., TakegaharaI.: Gallium-67 in transferrin-unbound form is taken up by inflamed liver of mouse treated with CC14.Ann. Nucl. Med., 4: 89–93, 1990.
61.
OkadaJ., YoshikawaK., ImazekiK.: The use of FDG-PET in the detection and management of malignant lymphoma.J. Nucl. Med., 32: 686–691, 1991.
62.
OkadaJ., YoshikawaK., ItamiM.: Positron emission tomography using fiorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.J. Nucl. Med., 33: 325–329, 1992.
63.
PatersonA.H.G., McCreadyV.R.: The current status of gallium 67 scanning.Br. J. Radiol., 48A: 944, 1975.
64.
PattersonA.H., PeckhamM.J., McCreadyV.R.: Value of gallium scanning in seminoma of the testis.Br. Med. J., 1: 1118–1121, 1976.
65.
PaulR.: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.J. Nucl. Med., 28: 288–292, 1987.
66.
PinskyS.M., BaileyT.B., BlomJ., GroveR.B., BorskiA., JohnsonM.C.: Ga-67 citrate in the staging of testicular malignancies.J. Nucl. Med., 14: 439–445, 1973.
67.
RamannaL., WaxmanA., BinneyG., WaxmanS., MirraJ., RosenG.: Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response.J. Nucl. Med., 31: 567–572, 1990.
68.
RossleighM.A., McCarthyW.H., MiltronG.W.: The role of gallium-67 studies in the management of malignant melanoma.Med. J. Aust., 140: 401–404, 1984.
69.
SephtonR.G., HarrisA.W.: Brief communication: Ga-67 citrate uptake by cultured tumor cells, stimulated by serum transferrin.J. Natl. Cancer Inst., 54: 1263–1266, 1975.
70.
SohnM.H., JonesB.J., WhitingJ.M., DatzF.L., LynchR.E., MortonA.: Distribution of Ga-67 in normal and hypotransferrinemic tumor-bearing mice.J. Nucl. Med., 34: 2135–2143, 1993.
71.
SoutheeA.E., KaplanW.D., JochelsonM.S.: Gallium imaging in metastatic and recurrent soft-tissue sarcoma.J. Nucl. Med., 33: 1594–1599, 1992.
72.
SoutheeA.E., McLauglinA.F., JoshuaD.E.: Gallium scanning as a predictor of outcome in mediastinal Hodgkin's disease.Eur. J. Nucl. Med.,15: 547, 1989.
73.
SoutheeA.E., WylieB.R., McLaughlinA.F., JoshuaD.E., KronenbergH., MorrisJ.G.: Gallium scintigraphy in the management of mediastinal Hodgkin's disease.Aust. NZ. J. Med.,18: 508, 1988.
74.
SturrockA., AlexanderJ., LambJ., CravenC.M., KaplanJ.: Characterization of a transferrin-independent uptake system for iron in HeLa cells.J. Biol. Chem., 265: 3139–3145, 1990.
75.
TsanM.F., ChenW.Y., ScheffelU., WagnerH.N.: Studies on gallium accumulation in inflammatory lesions: 1. Gallium uptake by human polymorphonuclear leukocytes.J. Nucl. Med., 19: 36–43, 1985.
TurnerD.A., FordhamE.W., AliA.: Gallium 67 imaging in the management of Hodgkin's disease and other malignant lymphomas.Semin. Nucl. Med., 8: 205–218, 1978.
78.
TurnerD.A., GottschalkA., HofferP.B., HarperP.V., MorganE., UltmannJ.E.: Gallium-67 scanning in the staging of Hodgkin's disease.IAEA, Vienna, pp. 615–629, 1973.
79.
TurnerD.A., PinskyS.M., GottschalkA., HofferP.B., UltmannJ.E., HarperP.V.: The use of Ga-67 scanning in the staging of Hodgkin's disease.Radiology, 103: 97–101, 1972.
80.
VostrejsM., MoranP.L., SeligmanP.J.: Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation.J. Clin. Invest., 82: 331–339, 1988.
81.
WaxmanA., SiemsenJ., LevinA.M.: Radiographic and radionuclide imaging in multiple myeloma: the role of gallium scintigraphy.Concise communication. J. Nucl. Med., 22: 232–236, 1981.
82.
WeeksJ.C., YeapB.Y., CanellosG.P.: Value of follow-up procedures on patients with large cell lymphoma who achieve a complete remission.Clin. Oncol., 9: 1196–1201, 1991.
83.
WeinerR.E., HofferP.B., ThakurM.L.: Lactoferrin: its role as a Ga-67 binding protein from polymorphonuclear leukocytes.J. Nucl. Med., 22: 32–37, 1981.
84.
WongH., TernerU.K., EnglishD.: The role of transferrin in the in vivo uptake of gallium-67 in a canine tumor.Int. J. Nucl. Med. Biol., 7: 9–16, 1980.
85.
WylieB.R., SoutheeA.E., JoshuaD.E.: Gallium scanning in the management of mediastinal Hodgkin's disease.Eur. J. Hematol., 42: 344–347, 1989.
86.
YehS.D.J., RosenG., CapattosB., BenuaR.S.: Semiquantative gallium scintigraphy in patients with osteogenic sarcoma.Clin. Nucl. Med., 9: 175–183, 1984.
